ABIONYX Pharma Announces Its Financial Calendar for the Year 2025
13 Janvier 2025 - 6:00PM
Business Wire
Regulatory News:
ABIONYX Pharma (FR0012616852 - ABNX - PEA PME eligible),
a new generation biotech company dedicated to the discovery and
development of innovative therapies based on the world’s only
natural recombinant apoA-I, today announces its financial calendar
for 2025.
Events
Dates*
Cash position and activity update for
Q4 2024
Thursday, February 27, 2025
2024 Full-Year Results
Thursday, March 6, 2025
Cash position and activity update for
Q1 2025
Wednesday, May 28, 2025
Cash position and activity update for
Q2 2025
Thursday, August 28, 2025
2025 Half-Year Results
Thursday, September 25, 2025
Cash position and activity update for
Q3 2025
Tuesday, November 25, 2025
* indicative dates subject to change
About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on
developing innovative medicines for diseases where there is no
effective or existing treatment, even the rarest ones. The company
expedites the development of novel therapeutics through an
extensive expertise in lipid science and a differentiated
apoA-I-based technology platform. ABIONYX Pharma is committed to
radically improving treatment outcomes in Sepsis and critical
care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250113509882/en/
NewCap Investor relations Nicolas Fossiez Louis-Victor
Delouvrier abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 00 15
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Déc 2024 à Jan 2025
Abionyx Pharma (EU:ABNX)
Graphique Historique de l'Action
De Jan 2024 à Jan 2025
